Alexion pulls Soliris vials on particle-contamination worries

Alexion ($ALXN) had to recall more vials of its rare-disease treatment Soliris because particles were found in some of them. The move comes as Roche ($RHHBY) is reportedly eyeing a bid for the U.S.-based drugmaker. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.